AU2021359638A1 - Therapeutic radiolabelled conjugates and their use in therapy - Google Patents

Therapeutic radiolabelled conjugates and their use in therapy Download PDF

Info

Publication number
AU2021359638A1
AU2021359638A1 AU2021359638A AU2021359638A AU2021359638A1 AU 2021359638 A1 AU2021359638 A1 AU 2021359638A1 AU 2021359638 A AU2021359638 A AU 2021359638A AU 2021359638 A AU2021359638 A AU 2021359638A AU 2021359638 A1 AU2021359638 A1 AU 2021359638A1
Authority
AU
Australia
Prior art keywords
compound
formula
gsao
compound according
nodaga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021359638A
Other languages
English (en)
Inventor
Ivan HO SHON
Philip Hogg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centenary Institute of Cancer Medicine and Cell Biology
The University of Sydney
Original Assignee
Centenary Inst Of Cancer Medicine And Cell Biology
Centenary Institute of Cancer Medicine and Cell Biology
The University of Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020903727A external-priority patent/AU2020903727A0/en
Application filed by Centenary Inst Of Cancer Medicine And Cell Biology, Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney filed Critical Centenary Inst Of Cancer Medicine And Cell Biology
Publication of AU2021359638A1 publication Critical patent/AU2021359638A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2021359638A 2020-10-14 2021-10-14 Therapeutic radiolabelled conjugates and their use in therapy Pending AU2021359638A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020903727 2020-10-14
AU2020903727A AU2020903727A0 (en) 2020-10-14 Conjugates and their use in therapy
PCT/AU2021/051203 WO2022077068A1 (en) 2020-10-14 2021-10-14 Therapeutic radiolabelled conjugates and their use in therapy

Publications (1)

Publication Number Publication Date
AU2021359638A1 true AU2021359638A1 (en) 2023-06-01

Family

ID=81207378

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021359638A Pending AU2021359638A1 (en) 2020-10-14 2021-10-14 Therapeutic radiolabelled conjugates and their use in therapy

Country Status (10)

Country Link
US (1) US20230398240A1 (cg-RX-API-DMAC7.html)
EP (1) EP4228710A4 (cg-RX-API-DMAC7.html)
JP (1) JP7890301B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230130610A (cg-RX-API-DMAC7.html)
CN (1) CN116472068A (cg-RX-API-DMAC7.html)
AU (1) AU2021359638A1 (cg-RX-API-DMAC7.html)
CA (1) CA3195410A1 (cg-RX-API-DMAC7.html)
IL (1) IL302033A (cg-RX-API-DMAC7.html)
MX (1) MX2023004327A (cg-RX-API-DMAC7.html)
WO (1) WO2022077068A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220152229A1 (en) 2019-04-12 2022-05-19 Centenary Institute Of Cancer Medicine And Cell Biology Conjugates and their use as imaging agents
US20250269072A1 (en) * 2021-10-14 2025-08-28 Centenary Institute Of Cancer Medicine And Cell Biology Processes for preparing radiolabelled conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100418585C (zh) * 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
WO2016088116A1 (en) * 2014-12-05 2016-06-09 University Health Network Use of antioxidants as radio-protective agents
LT3275883T (lt) 2015-03-25 2021-08-25 Fujifilm Corporation Naujo azotą turinčio junginio arba jo druskos gamybos būdas ir jo tarpinio junginio gamyba
US20160367620A1 (en) * 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
US20220152229A1 (en) * 2019-04-12 2022-05-19 Centenary Institute Of Cancer Medicine And Cell Biology Conjugates and their use as imaging agents

Also Published As

Publication number Publication date
CN116472068A (zh) 2023-07-21
JP7890301B2 (ja) 2026-07-14
IL302033A (en) 2023-06-01
KR20230130610A (ko) 2023-09-12
US20230398240A1 (en) 2023-12-14
MX2023004327A (es) 2023-08-30
CA3195410A1 (en) 2022-04-21
EP4228710A4 (en) 2025-04-09
EP4228710A1 (en) 2023-08-23
WO2022077068A1 (en) 2022-04-21
JP2023547954A (ja) 2023-11-14

Similar Documents

Publication Publication Date Title
EP3498308B1 (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
AU2009200201B2 (en) Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US12296030B2 (en) Conjugates and their use as imaging agents
US20230398240A1 (en) Therapeutic radiolabelled conjugates and their use in therapy
JP2022538478A (ja) 前立腺特異的膜抗原(psma)リガンド及びその使用
US9050378B2 (en) N2S2 chelate-targeting ligand conjugates
JP2023523226A (ja) Psma結合リガンドを放射標識するための方法及びそのキット
JP2022549258A (ja) セラノスティックスとして使用するための放射性標識grprアンタゴニスト
US20250269072A1 (en) Processes for preparing radiolabelled conjugates
TW202332473A (zh) 放射性核種複合物的組合療法
HK40008701A (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
HK40008701B (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
HK40120870A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
HK1156514A (en) Ethylenedicysteine (ec)-drug conjugates, compositions and methods for tissue specific disease imaging